Myron Z. Holubiak

CIK: 0001199080

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)10 (71.4%)

Compensation grants

Other (G, F, J, C, D, …)4 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CTOR

CITIUS ONCOLOGY, INC.

DirectorOfficer

CTXR

Citius Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

CTOR
CITIUS ONCOLOGY, INC.
Sep 19, 2025
Award(A)
Direct
850K shares-
CTOR
CITIUS ONCOLOGY, INC.
Sep 19, 2025
Award(A)
Indirect
100K shares-
CTXR
Citius Pharmaceuticals, Inc.
Aug 8, 2025
Award(A)
Warrant to Purchase Common Stock
Direct
22.3K shares-
CTXR
Citius Pharmaceuticals, Inc.
Aug 8, 2025
Disposition(D)
Warrant to Purchase Common Stock
Direct
31.4K shares-
CTXR
Citius Pharmaceuticals, Inc.
Aug 8, 2025
Award(A)
Warrant to Purchase Common Stock
Direct
31.4K shares-
CTXR
Citius Pharmaceuticals, Inc.
Aug 8, 2025
Disposition(D)
Warrant to Purchase Common Stock
Direct
22.3K shares-
CTOR
CITIUS ONCOLOGY, INC.
Dec 12, 2024
Award(A)
Stock Option (Right to Buy)
Direct
300K shares-
CTOR
CITIUS ONCOLOGY, INC.
Dec 12, 2024
Award(A)
Stock Option (Right to Buy)
Indirect
50K shares-
CTXR
Citius Pharmaceuticals, Inc.
Nov 7, 2024
Award(A)
Stock Option (Right to Purchase Common Stock)
Direct
350K shares-
CTXR
Citius Pharmaceuticals, Inc.
Nov 7, 2024
Award(A)
Stock Option (Right to Buy)
Indirect
75K shares-
CTXR
Citius Pharmaceuticals, Inc.
Sep 25, 2024
Award(A)
Warrant to Purchase Common Stock
Direct
558.6K shares-
CTXR
Citius Pharmaceuticals, Inc.
Sep 25, 2024
Disposition(D)
Warrant to Purchase Common Stock
Direct
558.6K shares-
CTXR
Citius Pharmaceuticals, Inc.
Aug 14, 2024
Disposition(D)
Warrant to Purchase Common Stock
Direct
784.3K shares-
CTXR
Citius Pharmaceuticals, Inc.
Aug 14, 2024
Award(A)
Warrant to Purchase Common Stock
Direct
784.3K shares-

		Type	Shares	Price		Ownership
Sep 19, 2025	CTOR CITIUS ONCOLOGY, INC.	Award(A)	850,000	-	-	Direct
Sep 19, 2025	CTOR CITIUS ONCOLOGY, INC.	Award(A)	100,000	-	-	Indirect
Aug 8, 2025	CTXR Citius Pharmaceuticals, Inc.	Award(A) Warrant to Purchase Common Stock	22,344	-	-	Direct
Aug 8, 2025	CTXR Citius Pharmaceuticals, Inc.	Disposition(D) Warrant to Purchase Common Stock	31,373	-	-	Direct
Aug 8, 2025	CTXR Citius Pharmaceuticals, Inc.	Award(A) Warrant to Purchase Common Stock	31,373	-	-	Direct
Aug 8, 2025	CTXR Citius Pharmaceuticals, Inc.	Disposition(D) Warrant to Purchase Common Stock	22,344	-	-	Direct
Dec 12, 2024	CTOR CITIUS ONCOLOGY, INC.	Award(A) Stock Option (Right to Buy)	300,000	-	-	Direct
Dec 12, 2024	CTOR CITIUS ONCOLOGY, INC.	Award(A) Stock Option (Right to Buy)	50,000	-	-	Indirect
Nov 7, 2024	CTXR Citius Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Purchase Common Stock)	350,000	-	-	Direct
Nov 7, 2024	CTXR Citius Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	75,000	-	-	Indirect
Sep 25, 2024	CTXR Citius Pharmaceuticals, Inc.	Award(A) Warrant to Purchase Common Stock	558,597	-	-	Direct
Sep 25, 2024	CTXR Citius Pharmaceuticals, Inc.	Disposition(D) Warrant to Purchase Common Stock	558,597	-	-	Direct
Aug 14, 2024	CTXR Citius Pharmaceuticals, Inc.	Disposition(D) Warrant to Purchase Common Stock	784,314	-	-	Direct
Aug 14, 2024	CTXR Citius Pharmaceuticals, Inc.	Award(A) Warrant to Purchase Common Stock	784,314	-	-	Direct

1-14 of 14 transactions

About HOLUBIAK MYRON Z

HOLUBIAK MYRON Z (SEC CIK 0001199080) files insider reports with the SEC as Secretary of CITIUS ONCOLOGY, INC. (CTOR) and Vice Chairman of Citius Pharmaceuticals, Inc. (CTXR).

Signal8 holds 7 ownership filings by HOLUBIAK MYRON Z, all Form 4s, filed between Sep 27, 2024 and Dec 22, 2025. Those filings report 14 transactions, from Aug 14, 2024 to Sep 19, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on HOLUBIAK MYRON Z's filings is in CRANFORD, NJ.

Recent filings by HOLUBIAK MYRON Z

Sep 19, 2025: Grants or awards of CTOR shares (2 lines, Form 4, code A).
Aug 8, 2025: Grant or award of CTXR derivative securities (Form 4, code A).
Aug 8, 2025: Disposition to issuer transaction of CTXR derivative securities (Form 4, code D).
Aug 8, 2025: Grant or award of CTXR derivative securities (Form 4, code A).
Aug 8, 2025: Disposition to issuer transaction of CTXR derivative securities (Form 4, code D).

Other insiders filing for CITIUS ONCOLOGY, INC. (CTOR)

Peri Jonathan, Director
Webb Carol, Director
Czuczman Myron, Chief Medical Officer
Bartushak Jaime, Chief Financial Officer
Mazur Leonard L, Chief Executive Officer
Smith Robert Joseph, Director

How to read Form 4 transaction codes